A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
CG53135-05 (velafermin), a recombinant human fibroblast growth factor-20 (rhFGF-20) protein,
is under investigation for the prevention of oral mucositis. Oral mucositis is a commonly
occurring side effect of high-dose chemotherapy in patients undergoing autologous
hematopoietic stem cell transplant. The objective of this Phase II trial is to confirm the
safety and efficacy of CG53135-05 (velafermin) when administered as a single dose to patients
at risk for developing oral mucositis.